



Durysta™ (bimatoprost implant, for intracameral administration)

When requesting Durysta™ (bimatoprost implant), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Durysta (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Coverage Guidelines

Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

An individual must meet **all** of the following criteria for authorization:

- Is 18 years of age or older;
- Is **not** receiving re-treatment of eye(s) previously treated with Durysta;
- Meets the following criteria:
 - o Has experienced inadequate efficacy or severe adverse events to at least two ophthalmic prostaglandins (as monotherapy or concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension (e.g., bimatoprost ophthalmic solution, latanoprost ophthalmic solution, travoprost ophthalmic solution; latanoprostene bunod ophthalmic solution, and tafluprost ophthalmic solution); AND
 - o Has experienced inadequate efficacy or severe adverse events to at least two ophthalmic products (as monotherapy or concomitant therapy) from two different pharmacologic classes for the treatment of open-angle glaucoma or ocular hypertension (e.g., beta-blockers, alpha-agonist (brimonidine), carbonic anhydrase inhibitors, and rho kinase inhibitor (netarsudil); AND
- Durysta is prescribed by or in consultation with an ophthalmologist.

Approval duration: 1 dose (one implant per treated eye; a total of two implants per patient)

Dosing Recommendation

Approve up to one Durysta implant per treated eye(s) [two implants per patient].

References

1. Durysta™ [prescribing information]. Madison, NJ: Allergan USA, Inc; March 2020.
2. Boyd K. Glaucoma. Available at: <https://www.aao.org/eye-health/diseases/what-is-glaucoma>. Accessed on April 14, 2021.
3. Gedde SJ, Vinod K, Wright MW, et al. Primary open-angle glaucoma Preferred Practice Pattern® guidelines. The American Academy of Ophthalmology. 2020. Available at: <http://www.aao.org/guidelines-browse?filter=preferredpracticepatterns>. Accessed on April 14, 2021.
4. Facts and Comparisons® Online. Wolters Kluwer Health, Inc.; 2021. Available at: <http://online.factsandcomparisons.com/login.aspx?url=/index.aspx&q=netarsudil>. Accessed on April 14, 2021. Search term: netarsudil.